During the last session, Pyxis Oncology Inc (NASDAQ:PYXS)’s traded shares were 7.91 million, with the beta value of the company hitting 1.29. At the end of the trading day, the stock’s price was $2.08, reflecting an intraday loss of -45.55% or -$1.74. The 52-week high for the PYXS share is $6.85, that puts it down -229.33 from that peak though still a striking 35.1% gain since the share price plummeted to a 52-week low of $1.35. The company’s market capitalization is $123.69M, and the average intraday trading volume over the past 10 days was 1.26 million shares, and the average trade volume was 609.93K shares over the past three months.
Pyxis Oncology Inc (PYXS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. PYXS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Pyxis Oncology Inc (PYXS) registered a -45.55% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -45.55% in intraday trading to $2.08, hitting a weekly high. The stock’s 5-day price performance is -51.40%, and it has moved by -42.38% in 30 days. Based on these gigs, the overall price performance for the year is 45.45%. The short interest in Pyxis Oncology Inc (NASDAQ:PYXS) is 5.86 million shares and it means that shorts have 10.78 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 79.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $10 respectively. As a result, PYXS is trading at a discount of -380.77% off the target high and -236.54% off the low.
Pyxis Oncology Inc (PYXS) estimates and forecasts
Statistics show that Pyxis Oncology Inc has outperformed its competitors in share price, compared to the industry in which it operates. Pyxis Oncology Inc (PYXS) shares have gone down -45.55% during the last six months, with a year-to-date growth rate more than the industry average at 44.32% against 16.60.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -118.72%. While earnings are projected to return 41.35% in 2024, the next five years will return 34.60% per annum.
PYXS Dividends
Pyxis Oncology Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
Pyxis Oncology Inc insiders own 24.54% of total outstanding shares while institutional holders control 54.52%, with the float percentage being 72.25%. DEEP TRACK CAPITAL, LP is the largest shareholder of the company, while 125.0 institutions own stock in it. As of 2024-06-30, the company held over 4.18 million shares (or 8.1578% of all shares), a total value of $13.85 million in shares.
The next largest institutional holding, with 3.86 million shares, is of LAURION CAPITAL MANAGEMENT LP’s that is approximately 7.5282% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $12.78 million.
Also, the Mutual Funds coming in first place with the largest holdings of Pyxis Oncology Inc (PYXS) shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund. Data provided on Sep 30, 2024 indicates that iShares Russell 2000 ETF owns about 1.24 shares. This amounts to just over 2.09 percent of the company’s overall shares, with a $2.61 million market value. The same data shows that the other fund manager holds slightly less at 905.32, or about 1.52% of the stock, which is worth about $1.9 million.
